Antithrombotic strategies in gene therapy

Keith M. Channon, Brian H. Annex

Research output: Contribution to journalArticle

Abstract

Advances in the field of molecular medicine are making gene therapy a viable treatment strategy for the next millennium. Indeed, over the past 10 years, a number of improvements have occurred that have resulted in an increased interest in gene therapy for the treatment of diseases in cardiovascular medicine. Because antithrombotic and anticoagulation therapy generally involves the systemic administration of agents that target a small region of the vasculature, localized and controlled delivery of specific genes could offer enormous potential to treat a number of life-threatening diseases. In addition, gene therapy may allow sustained antithrombotic or anticoagulant treatment when prolonged systemic administration is undesirable. Gene therapy for antithrombotic strategies can involve a number of different approaches. This could include inhibition of coagulation factors, over-expression of anticoagulant factors, o modulation of endothelial biology to make thrombus formation or propagation unfavorable. Preclinical data regarding these different strategies are reviewed and their potential limitations discussed.

Original languageEnglish (US)
Pages (from-to)34-38
Number of pages5
JournalCurrent Cardiology Reports
Volume2
Issue number1
DOIs
StatePublished - Dec 1 2000
Externally publishedYes

Fingerprint

Genetic Therapy
Anticoagulants
Molecular Medicine
Blood Coagulation Factors
Therapeutics
Thrombosis
Cardiovascular Diseases
Medicine
Genes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Antithrombotic strategies in gene therapy. / Channon, Keith M.; Annex, Brian H.

In: Current Cardiology Reports, Vol. 2, No. 1, 01.12.2000, p. 34-38.

Research output: Contribution to journalArticle

Channon, Keith M. ; Annex, Brian H. / Antithrombotic strategies in gene therapy. In: Current Cardiology Reports. 2000 ; Vol. 2, No. 1. pp. 34-38.
@article{6e60863304394d5aa58b34992cab98bd,
title = "Antithrombotic strategies in gene therapy",
abstract = "Advances in the field of molecular medicine are making gene therapy a viable treatment strategy for the next millennium. Indeed, over the past 10 years, a number of improvements have occurred that have resulted in an increased interest in gene therapy for the treatment of diseases in cardiovascular medicine. Because antithrombotic and anticoagulation therapy generally involves the systemic administration of agents that target a small region of the vasculature, localized and controlled delivery of specific genes could offer enormous potential to treat a number of life-threatening diseases. In addition, gene therapy may allow sustained antithrombotic or anticoagulant treatment when prolonged systemic administration is undesirable. Gene therapy for antithrombotic strategies can involve a number of different approaches. This could include inhibition of coagulation factors, over-expression of anticoagulant factors, o modulation of endothelial biology to make thrombus formation or propagation unfavorable. Preclinical data regarding these different strategies are reviewed and their potential limitations discussed.",
author = "Channon, {Keith M.} and Annex, {Brian H.}",
year = "2000",
month = "12",
day = "1",
doi = "10.1007/s11886-000-0023-4",
language = "English (US)",
volume = "2",
pages = "34--38",
journal = "Current Cardiology Reports",
issn = "1523-3782",
publisher = "Current Medicine Group",
number = "1",

}

TY - JOUR

T1 - Antithrombotic strategies in gene therapy

AU - Channon, Keith M.

AU - Annex, Brian H.

PY - 2000/12/1

Y1 - 2000/12/1

N2 - Advances in the field of molecular medicine are making gene therapy a viable treatment strategy for the next millennium. Indeed, over the past 10 years, a number of improvements have occurred that have resulted in an increased interest in gene therapy for the treatment of diseases in cardiovascular medicine. Because antithrombotic and anticoagulation therapy generally involves the systemic administration of agents that target a small region of the vasculature, localized and controlled delivery of specific genes could offer enormous potential to treat a number of life-threatening diseases. In addition, gene therapy may allow sustained antithrombotic or anticoagulant treatment when prolonged systemic administration is undesirable. Gene therapy for antithrombotic strategies can involve a number of different approaches. This could include inhibition of coagulation factors, over-expression of anticoagulant factors, o modulation of endothelial biology to make thrombus formation or propagation unfavorable. Preclinical data regarding these different strategies are reviewed and their potential limitations discussed.

AB - Advances in the field of molecular medicine are making gene therapy a viable treatment strategy for the next millennium. Indeed, over the past 10 years, a number of improvements have occurred that have resulted in an increased interest in gene therapy for the treatment of diseases in cardiovascular medicine. Because antithrombotic and anticoagulation therapy generally involves the systemic administration of agents that target a small region of the vasculature, localized and controlled delivery of specific genes could offer enormous potential to treat a number of life-threatening diseases. In addition, gene therapy may allow sustained antithrombotic or anticoagulant treatment when prolonged systemic administration is undesirable. Gene therapy for antithrombotic strategies can involve a number of different approaches. This could include inhibition of coagulation factors, over-expression of anticoagulant factors, o modulation of endothelial biology to make thrombus formation or propagation unfavorable. Preclinical data regarding these different strategies are reviewed and their potential limitations discussed.

UR - http://www.scopus.com/inward/record.url?scp=0033649147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033649147&partnerID=8YFLogxK

U2 - 10.1007/s11886-000-0023-4

DO - 10.1007/s11886-000-0023-4

M3 - Article

C2 - 10980870

AN - SCOPUS:0033649147

VL - 2

SP - 34

EP - 38

JO - Current Cardiology Reports

JF - Current Cardiology Reports

SN - 1523-3782

IS - 1

ER -